Clostridium difficile-associated diarrhea

被引:10
作者
Bujanda, Luis [1 ]
Cosme, Angel [2 ]
机构
[1] Hosp Donostia, Serv Aparato Digest, Ctr Invest Biomed Enfermedades Hepat & Digest, CIBEREHD, San Sebastian, Spain
[2] Univ Basque Country, Inst Salud Carlos III, San Sebastian, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2009年 / 32卷 / 01期
关键词
Clostridium difficile; Diagnosis; Treatment; Diarrhea; Antibiotics; INTRAVENOUS IMMUNOGLOBULIN; CASE SERIES; COLITIS; VANCOMYCIN; DISEASE; OUTCOMES; METRONIDAZOLE; PREVENTION; DIAGNOSIS; TOLEVAMER;
D O I
10.1016/j.gastrohep.2008.02.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Clostridium difficile is the most frequent cause of nosocomial diarrhea and is a significant cause of morbidity among hospitalized patients. The inflammation is produced as a result of a non-specific response to toxins. In the last few years, a hypervirulent strain, NAP1/BI/027, has been reported. Symptoms usually consist of abdominal pain and diarrhea. The diagnosis should be suspected in any patient who develops diarrhea during antibiotic therapy or 6-8 weeks after treatment. Diagnosis should be confirmed by the detection of CD toxin in stool and by colonoscopy in special situations. The treatment of choice is metronidazole or vancomycin. In some patients who do not respond to this therapy or who have complications, subtotal colectomy may be required. Relapse is frequent and must be distinguished from reinfection. Prevention and control in healthcare settings requires careful attention. © 2008 Elsevier España, S.L. All rights reserved.
引用
收藏
页码:48 / 56
页数:9
相关论文
共 50 条
  • [21] Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea
    Golan, Yoav
    Epstein, Lauren
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (06): : 395 - 402
  • [22] Current and future treatment modalities for Clostridium difficile-associated disease
    Halsey, Jennifer
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (08) : 705 - 715
  • [23] Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis
    Hostler, Christopher J.
    Chen, Luke F.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (11) : 1529 - 1536
  • [25] Clostridium difficile-associated diarrhea in 200 Canadian children
    Morinville, V
    McDonald, J
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 19 (08): : 497 - 501
  • [26] The Use of Probiotics in the Prevention and Treatment of Antibiotic-Associated Diarrhea With Special Interest in Clostridium difficile-Associated Diarrhea
    Rohde, Cynthia L.
    Bartolini, Vickie
    Jones, Nicole
    NUTRITION IN CLINICAL PRACTICE, 2009, 24 (01) : 33 - 40
  • [27] Antibiotic-associated diarrhea due to Clostridium difficile
    Moskaliuk, V. D.
    Rudan, I. V.
    Balaniuk, I. V.
    Myronyk, O. V.
    Andrushchak, M. O.
    ZAPOROZHYE MEDICAL JOURNAL, 2018, (05) : 729 - 733
  • [28] Chilean consensus of prevention, diagnosis and treatment of Clostridium difficile-associated diarrhea
    Hernandez-Rocha, Cristian
    Pidal, Paola
    Cristina Ajenjo, M.
    Quera, Rodrigo
    Quintanilla, Marcela
    Lubascher, Jaime
    Irene Jemenao, M.
    Ibanez, Patricio
    Alvarez-Lobos, Manuel
    Diomedi, Alexis
    Marcotti, Alejandra
    Acuna, Mirta
    Arab, Juan P.
    Riquelme, Arnoldo
    Candia, Roberto
    Carvajal, Sergio
    REVISTA CHILENA DE INFECTOLOGIA, 2016, 33 (01): : 99 - 118
  • [29] Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease
    Bossuyt, Peter
    Verhaegen, Jan
    Van Assche, Gert
    RutgeertS, Paul
    Vermeire, Severine
    JOURNAL OF CROHNS & COLITIS, 2009, 3 (01) : 4 - 7
  • [30] Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients
    Gellad, Z. F.
    Alexander, B. D.
    Liu, J. K.
    Griffith, B. C.
    Meyer, A. M.
    Johnson, J. L.
    Muir, A. J.
    TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (04) : 276 - 280